• All sections
  • C - Chemistrymetallurgy
  • C07D - Heterocyclic compounds
  • C07D 263/06 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by oxygen atoms, attached to ring carbon atoms

Patent holdings for IPC class C07D 263/06

Total number of patents in this class: 99

10-year publication summary

4
7
7
10
3
2
4
5
4
4
2017 2018 2019 2020 2021 2022 2023 2024 2025 2026

Principal owners for this class

Owner
All patents
This class
Enzo Therapeutics, Inc.
28
9
Virginia Commonwealth University
661
7
Merck Sharp & Dohme Corp.
2183
5
Henkel AG & Co. KGaA
10768
4
Baker Hughes Incorporated
4916
3
Dong-A ST Co., Ltd.
142
3
Oncternal Therapeutics, Inc.
35
3
Angus Chemical Company
99
2
Daewoong Pharmaceutical Co., Ltd.
366
2
Nosopharm
9
2
Cyclerion Therapeutics, Inc.
83
2
Nutrition & Biosciences USA 2, LLC
67
2
Merck Sharp & Dohme LLC
3736
2
Seraph Biotech Consulting, LLC
9
2
The Procter & Gamble Company
21853
1
Novartis AG
10178
1
The Regents of the University of California
20802
1
Genentech, Inc.
4115
1
Centre National de La Recherche Scientifique
11055
1
Rohm and Haas Company
2942
1
Other owners 45